The Benefic Effects of Cannabis on Patients with Multiple Sclerosis

In accordance with recently ran experiments, cannabis can be viewed as an effective remedy for patients identified as having multiple sclerosis. While initially the symptomatic improvements experienced by patients with multiple sclerosis who have been administered cannabinoid products were thought to be determined solely by emotional aspects, after research has revealed that cannabis actually reduces muscular spasms and stiffness trait into multiple sclerosis patients. The benefic effects of cannabis on patients with multiple sclerosis are confirmed by long-term and short-term controlled medical studies.

In 2003, a team of investigators from the Peninsula Medical School in Exeter, UK have made public that the consequences of a series of long-term and short-term studies on the outcomes of cannabinoids among patients with multiple sclerosis. The previously conducted studies involved the active involvement of around 600 patients using advanced-stage multiple sclerosis. The participants were divided into two distinctive categories: the first group received cannabinoid chemicals in equal doses, while the next group received placebo medications within a period of time of 15 weeks. At the close of the experiment, the majority of patients that were administered cannabinoids experienced appreciable symptomatic improvements, having less muscular pain and being confronted by milder muscle spasticity (less conspicuous muscle strain ). Unlike the group that received cannabinoid compounds over the entire period of the analysis, the control group (patients that received placebo medications) undergone no improvements in their general condition.

To be able to verify the significance of the findings to discard any doubts concerning the efficiency of cannabis from ameliorating the symptoms of multiple sclerosis, the study was later repeated. The ulterior analysis was conducted over a span of 1-2 months, and involved the participation of the same subjects. However, this period the participants were divided into 3 distinctive groups rather than two as in case of their preceding experiment. The first group received pills of D9-tetrahydrocannabinol (THC) – the most active component in cannabis, the next category received natural cannabis extracts, while the third group received placebo medications.

At the close of the experiment, both patients were carefully evaluated and analyzed by a group of physiotherapists and neurologists. The most effective results were obtained on the list of patients belonging to the primary study group, the vast majority of subjects who’ve received equal doses of THC experiencing considerable improvements in their own symptoms. The patients at the next study group experienced slight improvements in their symptoms, whereas the patients in the next category believed no changes within their situation.